文献速递免疫规划卫生政策与健康促进

轮状病毒疫苗的全球经济学评价:系统综述

Global economic evaluations of rotavirus vaccines: A systematic review.
PubMed 文献 · Vaccine · 2017-05-11

该研究系统检索多个数据库至2015年11月,纳入104项轮状病毒疫苗经济学评价研究。结果显示,常规大规模接种在低收入国家相比不接种的增量成本效果比从成本节约到极具成本效果,在中收入国家从成本节约到具成本效果,而部分高收入国家因疫苗价格未补贴而报告不具成本效果。

要点

  • 纳入104项轮状病毒疫苗经济学评价研究,多数来自高收入国家。
  • 低收入国家常规接种相比不接种的增量成本效果比从成本节约到极具成本效果。
  • 中收入国家接种的增量成本效果比从成本节约到具成本效果。

核心结论

  • 总体而言,轮状病毒大规模接种通常具成本效果,尤其在低、中收入国家,取决于外部对疫苗价格的补贴。
  • 在部分高收入国家,按市场价格接种可能不具成本效果。

研究设计与样本

  • 系统综述,检索Medline、Embase、NHS EED、EconLit、CEA Registry、SciELO、LILACS、CABI-Global Health Database、Popline、World Bank e-Library和WHOLIS,纳入从建库至2015年11月发表的完整经济学评价研究。
  • 共纳入104项评估轮状病毒疫苗预防轮状病毒感染的经济学评价研究。

主要发现

  • 多数研究在高收入国家开展,许多研究采用每避免一个DALY或每获得一个QALY的增量成本效果比报告成本-效用分析。
  • 低收入国家中,常规大规模接种相比不接种的增量成本效果比从成本节约到极具成本效果。
  • 中收入国家中,接种的增量成本效果比从成本节约到具成本效果。
  • 部分高收入国家因外部资助者提供低价格或无补贴价格而报告不具成本效果。

临床怎么用

  • 本系统综述为卫生政策制定者和卫生专业人员考虑将轮状病毒疫苗接种作为国家规划时提供支持信息。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: World Health Organization (WHO) recommends Rotavirus vaccines to prevent and control rotavirus infections. Economic evaluations (EE) have been considered to support decision making of national policy. Summarizing global experience of the economic value of rotavirus vaccines is crucial in order to encourage global WHO recommendations for vaccine uptake. Therefore, a systematic review of economic evaluations of rotavirus vaccine was conducted. METHODS: We searched Medline, Embase, NHS EED, EconLit, CEA Registry, SciELO, LILACS, CABI-Global Health Database, Popline, World Bank - e-Library, and WHOLIS. Full economic evaluations studies, published from inception to November 2015, evaluating Rotavirus vaccines preventing Rotavirus infections were included. The methods, assumptions, results and conclusions of the included studies were extracted and appraised using WHO guide for standardization of EE of immunization programs. RESULTS: 104 relevant studies were included. The majority of studies were conducted in high-income countries. Cost-utility analysis was mostly reported in many studies using incremental cost-effectiveness ratio per DALY averted or QALY gained. Incremental cost per QALY gained was used in many studies from high-income countries. Mass routine vaccination against rotavirus provided the ICERs ranging from cost-saving to highly cost-effective in comparison to no vaccination among low-income countries. Among middle-income countries, vaccination offered the ICERs ranging from cost-saving to cost-effective. Due to low- or no subsidized price of rotavirus vaccines from external funders, being not cost-effective was reported in some high-income settings. CONCLUSION: Mass vaccination against rotavirus was generally found to be cost-effective, particularly in low- and middle-income settings according to the external subsidization of vaccine price. On the other hand, it may not be a cost-effective intervention at market price in some high-income settings. This systematic review provides supporting information to health policy-makers and health professionals when considering rotavirus vaccination as a national program.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Kotirum S, Vutipongsatorn N, Kongpakwattana K, et al. Global economic evaluations of rotavirus vaccines: A systematic review. Vaccine. 2017. PMID: 28504193. doi:10.1016/j.vaccine.2017.04.051

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。